Edgen Stock·Dec 02 2025, 02:09Back
Adagene Secures Licensing Deal with Third Arc Bio for Cancer Therapy Platform, Valued Up to $840M
Edgen Stock·Dec 02 2025, 02:09
[1] Adagene inks licensing deal with Third Arc Bio | The Pharmaletter (https://www.thepharmaletter.com/biotechnology ...)[2] Adagene Announces Licensing Agreement with Third Arc Bio for ... (https://finance.yahoo.com/news/adagene-announ ...)[3] Adagene and Third Arc Bio collaborate on masked CD3 T cell ... (https://www.ddw-online.com/adagene-and-third- ...)
